The Business Research Company has updated its global market reports with latest data for 2024 and projections up to 2033.
The Insulin biosimilars Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Insulin biosimilars Market:
https://www.thebusinessresearchcompany.com/report/insulin-biosimilars-global-market-report
According to The Business Research Company’s Insulin biosimilars Global Market Report 2024, The insulin biosimilars market size has grown rapidly in recent years. It will grow from $2.64 billion in 2023 to $3.08 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to increased diabetes prevalence, growing healthcare costs, expanding access to diabetes treatment, market competition and price pressures, regulatory support and approval pathways.The insulin biosimilars market size is expected to see rapid growth in the next few years. It will grow to $5.41 billion in 2028 at a compound annual growth rate (CAGR) of 15.2%.
The rising prevalence of diabetes is expected to drive the growth of the insulin biosimilars market in the coming years. Diabetes, a chronic metabolic disorder characterized by elevated blood sugar levels, requires insulin therapy for management. Biosimilars offer an alternative treatment option for insulin therapy, addressing the increasing demand for diabetes management. For example, according to the International Diabetes Federation (IDF) in December 2021, the global number of individuals with diabetes is projected to reach 643 million by 2030 and 783 million by 2045. Moreover, there are currently over 1.2 million children and adolescents living with type 1 diabetes. This significant rise in diabetes cases underscores the growing need for insulin biosimilars to meet treatment demands. Consequently, the increasing prevalence of diabetes is a key factor driving the growth of the insulin biosimilars market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10661&type=smp
The insulin biosimilars market covered in this report is segmented –
1) By Biosimilars Type: Rapid Acting biosimilars, Long Acting biosimilars, Premixed Acting biosimilars
2) By Disease Indication Type: Type I Diabetes, Type II Diabetes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End User: Hospitals, Ambulatory Surgical Centers, Other End Users
Top Major Players
Eli Lilly and Company,
Boehringer Ingelheim GmbH,
Merck & Co Inc.,
Pfizer Inc.,
Biocon Ltd.
The insulin biosimilars market report table of contents includes:
1. Executive Summary
- Insulin biosimilars Market Characteristics
- Insulin biosimilars Market Trends And Strategies
- Insulin biosimilars Market – Macro Economic Scenario
- Global Insulin biosimilars Market Size and Growth
- Insulin biosimilars Market Segmentation
- Insulin biosimilars Market Regional And Country Analysis
……………
- Key Mergers And Acquisitions In The Insulin biosimilars Market
- Insulin biosimilars Market Future Outlook and Potential Analysis
- Appendix
List Of Tables :
Table 1: Global Historic Market Growth, 2018-2023, $ Billion
Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
Table 3: Global Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Table 4: Global Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Table 5: Global Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
…………
Table 75: Eli Lilly and Company Financial Performance
Table 76: Boehringer Ingelheim GmbH Financial Performance
Table 77: Merck & Co Inc. Financial Performance
Table 78: Pfizer Inc. Financial Performance
Table 79: Biocon Ltd. Financial Performance
Read Related Reports :
https://topprnews.com/heating-oil-additives-market-growth/
https://goodprnews.com/heating-oil-additives-market-size-2/
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
